Drug Profile
Coronavirus vaccine - Sinovac Biotech
Alternative Names: SARS vaccine - Beijing Kexing Bio-productLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Beijing Kexing Bio-product Co
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Severe acute respiratory syndrome
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Severe acute respiratory syndrome in China
- 21 Mar 2007 Coronavirus vacine is still in phase I trials for Coronavirus infections in China
- 14 Dec 2004 Clinical data from a media release have been added to the Viral Infections immunogenicity section